Physician

Bruce W Porterfield, M.D.

According to 2025 Medicare claims, Bruce Porterfield, M.D. (NPI: 1962451377) practices medical oncology in the Panama City-Panama City Beach, FL market, with the plurality of this provider's patient population coming from Bay, FL. This provider's primary affiliated billing organization is OCALA ONCOLOGY CENTER PL (NPI: 1356300958; TIN: 900336929) and primary practice location at 32405-4587. Porterfield is affiliated with the Primary Care Alliance, LLC (ACO ID: D0010), participating under the REACH model.

Porterfield's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 124 traditional Medicare patients, billed 19,332 HCPCS/CPT codes, and received $296,654 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 227 prescription claims across 66 beneficiaries totaling $218,928 in drug costs, led by Exemestane (Exemestane). 2022 DME data shows 28 claims. Open Payments data shows 12 records totaling $242. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has fallen sharply in recent years, from $2,621,546 to $296,654. Similarly, Part D prescription costs have fallen sharply in recent years, from $1,329,598 to $218,928. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $9,234 to $1,438.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	920	278,890	$2,621,546
2016	871	217,443	$2,248,359
2017	820	163,011	$2,704,541
2018	896	190,892	$3,046,653
2019	948	244,365	$3,949,246
2020	915	302,964	$3,967,357
2021	874	258,957	$3,290,746
2022	163	492	$33,380
2023	202	998	$66,022
2024	124	19,332	$296,654

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	363	1,721	$1,329,598
2016	377	2,505	$3,016,554
2017	383	2,445	$3,323,483
2018	413	2,384	$4,507,899
2019	462	2,632	$5,423,292
2020	419	2,547	$5,762,781
2021	408	2,240	$4,754,240
2022	221	684	$385,217
2023	167	687	$606,015
2024	66	227	$218,928

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	121	$8,792
2016	N/R	82	$14,404
2017	11	63	$3,447
2018	11	164	$16,072
2019	N/R	161	$14,110
2020	13	62	$4,018
2021	N/R	32	$1,403
2022	N/R	28	$1,264
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	47	47	$125
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	35	71	$71
80053	Blood test, comprehensive group of blood chemicals	45	92	$10
36415	Insertion of needle into vein for collection of blood sample	65	142	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	61	144	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Exemestane	Exemestane	12	360	$727
Anastrozole	Anastrozole	33	1,677	$492
Ondansetron Odt	Ondansetron	12	140	$187
Acyclovir	Acyclovir	17	664	$174
Gabapentin	Gabapentin	13	450	$164

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	12	$242	BeiGene USA, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Bruce W. Porterfield, M.D.?

Tedicare shows public-source Medicare data for Bruce W. Porterfield, M.D. (NPI 1962451377), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Bruce W. Porterfield, M.D. have ACO affiliation data?

Bruce W. Porterfield, M.D. is shown with ACO affiliation data for Primary Care Alliance, LLC (REACH, ACO ID D0010).

What billing organization is linked to Bruce W. Porterfield, M.D.?

Bruce W. Porterfield, M.D. is linked to OCALA ONCOLOGY CENTER PL (billing NPI 1356300958) in the available physician profile data.

Does Bruce W. Porterfield, M.D. have Open Payments data?

Bruce W. Porterfield, M.D. has 12 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.